Report from Annual General Meeting in Intervacc

Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 15 May 2024, at which the following resolutions were made.

Adoption of the income statement and balance sheet

The AGM adopted the Board of Directors’ submitted income statement and balance sheet for the parent company and the group for the financial year 2023.

Appropriation of the company’s profit or loss

The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for the financial year 2023, and that the result shall be balanced in a new account.

Discharge from liability towards the members of the Board of Directors and the CEOs

The AGM resolved to discharge each of the members of the Board of Directors and the CEOs who have been active during the financial year 2023, from liability for the financial year 2023.

Board of Directors and auditor

The AGM resolved, in accordance with the Nomination Committee’s proposal, that the Board of Director shall consist of seven Board members without any deputies.

The AGM resolved, in accordance with the Nomination Committee’s proposal, to re-elect Håkan Björklund, Lisen Bratt Fredricson, Jan-Ingmar Flock, Lennart Johansson och Camilla Ramfelt McCarthy, and to elect Mathias Uhlen and Emil Billbäck, as Board members for the period up to and including the next AGM. Håkan Björklund was re-elected as the Board of Directors’ chairperson for the period up to and including the next AGM.

The AGM resolved, in accordance with the Nomination Committee’s proposal, that the fees to the Board of Directors shall be paid with SEK 280,000 to the Board of Directors’ chairperson and SEK 130,000 to each of the other Board members.

The AGM resolved, in accordance with the Nomination Committee’s proposal, to re-elect the registered public accounting firm Öhrlings PricewaterhouseCoopers AB as the company’s auditor for the period up to and including the next AGM, which intends to appoint the authorised public accountant Niclas Bergenmo as auditor in charge.

The AGM resolved that fees to the auditor shall be paid according to the current account.

Authorisation regarding issues

The AGM resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors, within the limits of the Articles of Association, with or without deviation from the shareholders’ preferential rights, on one or more occasions, until the next AGM, to resolve to increase the company’s share capital through issues of new shares, warrants and/or convertibles in the company. The total number of shares covered by such new issues may correspond to a total of no more than ten (10) percent of the shares in the company at the time of the AGM 2024.

Amendment of the Articles of Association regarding the limits of the share capital, and reduction of the share capital for allocation to non-restricted equity

The AGM resolved, in accordance with the Board of Directors’ proposal, to change the Articles of Association’s paragraph 4 regarding the limits for the share capital to not less than SEK 8,000,000 and not more than SEK 32,000,000, and on a reduction of the share capital by SEK 136,325,285.444635, without retirement of shares, for allocation to non-restricted equity.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: [email protected]

 

The information was submitted for publication, through the agency of the contact person set out above on May 15, 2024, 14.30 CET.

 

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [email protected], Phone: +46 (0)8 – 684 211 10